How do researchers and policy-makers decide on the value of health? Daniel Cressey looks at Britain's National Institute for Health and Clinical Excellence.
References
Thompson Coon, J. et al. Bevacizumab, Sorafenib tosylate, Sunitinib and Temsirolimus for Renal Cell Carcinoma: A Systematic Review and Economic Evaluation (Peninsula Technology Assessment Group, 2008).
Escudier, B. et al. Lancet 370, 2103-2111 (2007).
National Institute for Health and Clinical Excellence Final Appraisal Determination: Sunitinib for the First-line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma (NIH, 2009).
Additional information
See Editorial, see page 315 .
Related links
Rights and permissions
About this article
Cite this article
Cressey, D. Health economics: Life in the balance. Nature 461, 336–339 (2009). https://doi.org/10.1038/461336a
Published:
Issue Date:
DOI: https://doi.org/10.1038/461336a
- Springer Nature Limited
This article is cited by
-
Quantitative medical cost-effectiveness analysis of molecular-targeting cancer drugs in Japan
DARU Journal of Pharmaceutical Sciences (2013)